Literature DB >> 24227699

Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung.

Hope E Karnes1, Eric J Duncavage, Cory T Bernadt.   

Abstract

BACKGROUND: Molecular testing of cancer is increasingly critical to medicine. Next-generation sequencing (NGS) provides comprehensive, unbiased, and inexpensive mutation analysis of multiple genes with a single test. However, to the authors' knowledge, the usefulness of NGS in fine-needle aspiration (FNA) specimens, which may be the only specimens available, is unknown. Non-small cell lung cancer (NSCLC) is an ideal model in which to evaluate cytopathologic applications of NGS because FNA is used for diagnosis and staging and specific molecular therapeutic targets in NSCLC are known. Herein, the performance and quality of targeted NGS in FNA specimens from a small series of lung adenocarcinomas is evaluated.
METHODS: Sequence data were generated from FNA specimens and paired formalin-fixed paraffin-embedded (FFPE) tissues from 5 patients with lung adenocarcinoma. DNA was isolated from FNA aspirate smears and cores of FFPE tissue. Multiplex sequencing of 27 cancer-related genes was performed after hybrid capture enrichment. Read-quality metrics and single-nucleotide variant calls were compared.
RESULTS: The overall concordance of total reads across specimens was > 99% and the average concordance of single-nucleotide variants was 99.5%. The total reads generated, as well as the percentages of mapped, on-target, and unique reads were statistically indistinguishable (P > 0.05) between FFPE and FNA preparations. There also was no difference in the depth of sequencing coverage, including exon-level coverage in known lung cancer mutation hotspots.
CONCLUSIONS: DNA isolated from FNA slides yields comprehensive, accurate, and statistically indistinguishable sequence information compared with that obtained from FFPE tissue. These results support the integration of NGS technologies into the standard cytopathology workflow. Cancer (Cancer Cytopathol) 2014;122:104-13.
© 2013 American Cancer Society. © 2013 American Cancer Society.

Entities:  

Keywords:  KRAS; epidermal growth factor receptor (EGFR); fine-needle aspiration; lung adenocarcinoma; molecular testing; next-generation sequencing

Mesh:

Year:  2013        PMID: 24227699     DOI: 10.1002/cncy.21361

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  27 in total

Review 1.  [Cytological material for molecular pathology].

Authors:  L C Heukamp; L Bubendorf
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

2.  Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies.

Authors:  Sinchita Roy-Chowdhuri; Hui Chen; Rajesh R Singh; Savitri Krishnamurthy; Keyur P Patel; Mark J Routbort; Jawad Manekia; Bedia A Barkoh; Hui Yao; Sharjeel Sabir; Russell R Broaddus; L Jeffrey Medeiros; Gregg Staerkel; John Stewart; Rajyalakshmi Luthra
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

3.  Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients.

Authors:  Simon R Turner; Darren Buonocore; Patrice Desmeules; Natasha Rekhtman; Snjezana Dogan; Oscar Lin; Maria E Arcila; David R Jones; James Huang
Journal:  Lung Cancer       Date:  2018-03-07       Impact factor: 5.705

4.  The use of endobronchial ultrasound guided transbronchial needle aspiration specimens for next generation sequencing in non-small cell lung cancer: a clinical perspective.

Authors:  Sean Stoy; Septimiu Murgu
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 5.  Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors.

Authors:  George Miles; James Rae; Suresh S Ramalingam; John Pfeifer
Journal:  Semin Oncol       Date:  2015-07-14       Impact factor: 4.929

6.  Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS).

Authors:  Hussam Al-Kateb; TuDung T Nguyen; Karen Steger-May; John D Pfeifer
Journal:  Mol Oncol       Date:  2015-05-29       Impact factor: 6.603

7.  Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.

Authors:  Shiwang Wen; Lei Dai; Lei Wang; Wenjian Wang; Duoguang Wu; Kefeng Wang; Zhanghai He; Aodi Wang; Hui Chen; Peng Zhang; Xiaowei Dong; Yu-An Dong; Kai Wang; Ming Yao; Minghui Wang
Journal:  Oncologist       Date:  2019-03-22

8.  Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.

Authors:  Lester J Layfield; Sinchita Roy-Chowdhuri; Zubair Baloch; Hormoz Ehya; Kim Geisinger; Susan J Hsiao; Oscar Lin; Neal I Lindeman; Michael Roh; Fernando Schmitt; Nikoletta Sidiropoulos; Paul A VanderLaan
Journal:  Diagn Cytopathol       Date:  2016-08-26       Impact factor: 1.582

9.  FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.

Authors:  Amanda L Treece; Nathan D Montgomery; Nirali M Patel; Chris J Civalier; Leslie G Dodd; Margaret L Gulley; Jessica K Booker; Karen E Weck
Journal:  Cancer Cytopathol       Date:  2016-02-16       Impact factor: 5.284

10.  Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.

Authors:  Shuanzeng Wei; Virginia A LiVolsi; Kathleen T Montone; Jennifer J D Morrissette; Zubair W Baloch
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.